Venus Remedies, a leading research based global
pharmaceutical company has received approval for Market Authorisation from MHRA
(UK) via DCP route (which covers Ireland, Poland, Slovenia, Netherlands,
Finland, Austria, Slovakia, Denmark, Germany, Sweden, France and Italy also)
for its generic broad spectrum injectable antibiotic carbapenem. The company is
all set to launch this drug soon within this fiscal year.
Besides this, Venus has also got Market Authorisation for the same product from New Zealand's Ministry of Health. These grants have once again proved Venus Remedies’ R&D capabilities and its expertise in developing world class products with regulatory might.
At present, Meropenem sales account for $ 906 million across the globe, which is estimated to grow to $ 1006 million by 2012. These MA grants from both the territories have opened doors for Venus to enter into the highly lucrative penems market of 250 million USD in Europe and 20 million USD in New Zealand.
Presently, Venus is already selling Meropenem in various markets and is in the process of extending its footprints & sales operations in the most regulated markets also, which includes countries like Netherlands, France, Italy, Germany and few more. The company is successfully doing so through various tie-ups in these countries.
Besides this, Venus has also got Market Authorisation for the same product from New Zealand's Ministry of Health. These grants have once again proved Venus Remedies’ R&D capabilities and its expertise in developing world class products with regulatory might.
At present, Meropenem sales account for $ 906 million across the globe, which is estimated to grow to $ 1006 million by 2012. These MA grants from both the territories have opened doors for Venus to enter into the highly lucrative penems market of 250 million USD in Europe and 20 million USD in New Zealand.
Presently, Venus is already selling Meropenem in various markets and is in the process of extending its footprints & sales operations in the most regulated markets also, which includes countries like Netherlands, France, Italy, Germany and few more. The company is successfully doing so through various tie-ups in these countries.
No comments:
Post a Comment